Efficacy and Safety of Long-acting Injectable Cabotegravir and Rilpivirine in Improving HIV-1 Control in sub-Saharan Africa: Protocol for a Phase 3b Open-Label Randomized Controlled Trial (IMPALA) [version 1; peer review: 2 approved]

Efficacy and Safety of Long-acting Injectable Cabotegravir and Rilpivirine in Improving HIV-1 Control in sub-Saharan Africa: Protocol for a Phase 3b Open-Label Randomized Controlled Trial (IMPALA) [version 1; peer review: 2 approved]

Long-acting (LA) injectable therapy as treatment for HIV-1 infection offers reduced dosing frequency, increased discretion and provides an alternative to two or three-drug daily oral combinations. A parenteral LA formulation of cabotegravir (CAB) and rilpivirine (RPV) given by intramuscular (IM) inj...

Full description

Saved in:
Bibliographic Details
Main Authors: Fafa Addo Boateng, Daniel Grint, Eugene Ruzagira, Victoria Babirye Tumusiime, Ingrid Eshun-Wilsonova, Claire Norcross, Fiona Cresswell, Ubaldo Mushabe Bahemuka, Jonathan Kitonsa, Ayoub Kakande, Geofrey Kimbugwe, Fridah Mwendia, David S Lawrence, Veerle Van Eygen, Rodica Van Solingen
Format: Article
Language:English
Published: Wellcome 2025-03-01
Series:Wellcome Open Research
Subjects:
Treatment adherence
Long-acting
Cabotegravir
Rilpivirine
HIV-1
Antiretroviral therapy
eng
Online Access:https://wellcomeopenresearch.org/articles/10-166/v1
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://wellcomeopenresearch.org/articles/10-166/v1

Similar Items